News >

Randomized Trial Shows Importance of Radiation in NSCLC

Caroline Seymour
Published: Saturday, Dec 22, 2018

Michael D. Mix, MD

Michael D. Mix, MD

Stereotactic body radiation therapy (SBRT) has been a mainstay in the treatment of patients with early-stage non– small cell lung cancer (NSCLC), explained Michael D. Mix, MD, and results of a randomized phase II trial have confirmed its utility in patients with oligometastatic disease, as well.

“It has long been questioned whether or not aggressive local therapy to distant metastatic sites in NSCLC, as well as in other cancers, is worthwhile,” Mix said. “It’s exciting to see results showing that [this approach] can play a fairly important role in improving overall survival (OS) in addition to progression-free survival (PFS) in oligometastatic NSCLC.”

To be eligible for enrollment in the phase II trial, patients had to have 3 or fewer metastatic lesions. Those who did not progress after receiving frontline chemotherapy or targeted therapy were randomized to receive aggressive management with either surgery or radiation, with or without chemotherapy, or to receive standard-of-care chemotherapy or observation. Results were presented at the 2018 ASTRO Annual Meeting and showed median OS rates of 41.2 months and 17 months at 38.8 months of follow-up in the local consolidative arm and the standard-of-care arm, respectively.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Advances in™ Therapies for Patients With ALK-Positive Lung Cancers: More Options…More Decisions…Better OutcomesAug 30, 20191.5
Oncology Briefings™: Treating Advanced NSCLC Without Actionable MutationsAug 30, 20191.0
Publication Bottom Border
Border Publication
x